Wells Fargo’s KalVista Pharmaceuticals KALV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $482K | Sell |
23,927
-32,087
| -57% | -$517K | ﹤0.01% | 4193 |
|
|
2025
Q4 | $905K | Buy |
56,014
+18,770
| +50% | +$249K | ﹤0.01% | 4046 |
|
|
2025
Q3 | $454K | Buy |
37,244
+11,920
| +47% | +$165K | ﹤0.01% | 4374 |
|
|
2025
Q2 | $286K | Buy |
25,324
+2,462
| +11% | +$30.1K | ﹤0.01% | 4537 |
|
|
2025
Q1 | $264K | Buy |
22,862
+2,697
| +13% | +$27.5K | ﹤0.01% | 4508 |
|
|
2024
Q4 | $171K | Buy |
20,165
+4,543
| +29% | +$47K | ﹤0.01% | 4884 |
|
|
2024
Q3 | $181K | Sell |
15,622
-310
| -2% | -$3.9K | ﹤0.01% | 4652 |
|
|
2024
Q2 | $188K | Buy |
15,932
+1,373
| +9% | +$16K | ﹤0.01% | 4554 |
|
|
2024
Q1 | $173K | Buy |
14,559
+3,728
| +34% | +$49.7K | ﹤0.01% | 4560 |
|
|
2023
Q4 | $133K | Buy |
10,831
+3,400
| +46% | +$30.9K | ﹤0.01% | 4730 |
|
|
2023
Q3 | $71.6K | Sell |
7,431
-3,153
| -30% | -$32.2K | ﹤0.01% | 4975 |
|
|
2023
Q2 | $95.3K | Buy |
10,584
+5,027
| +90% | +$46.4K | ﹤0.01% | 5070 |
|
|
2023
Q1 | $43.7K | Buy |
5,557
+4,317
| +348% | +$32.2K | ﹤0.01% | 5231 |
|
|
2022
Q4 | $8.38K | Sell |
1,240
-8,021
| -87% | -$43K | ﹤0.01% | 5619 |
|
|
2022
Q3 | $134K | Sell |
9,261
-267
| -3% | -$3.73K | ﹤0.01% | 4454 |
|
|
2022
Q2 | $94K | Sell |
9,528
-4,238
| -31% | -$46.8K | ﹤0.01% | 4674 |
|
|
2022
Q1 | $203K | Sell |
13,766
-7,743
| -36% | -$111K | ﹤0.01% | 4972 |
|
|
2021
Q4 | $284K | Sell |
21,509
-58,687
| -73% | -$934K | ﹤0.01% | 5064 |
|
|
2021
Q3 | $1.4M | Sell |
80,196
-6,111
| -7% | -$124K | ﹤0.01% | 3954 |
|
|
2021
Q2 | $2.07M | Buy |
86,307
+55,998
| +185% | +$1.47M | ﹤0.01% | 3664 |
|
|
2021
Q1 | $779K | Sell |
30,309
-7,868
| -21% | -$207K | ﹤0.01% | 4417 |
|
|
2020
Q4 | $726K | Sell |
38,177
-11,604
| -23% | -$199K | ﹤0.01% | 4257 |
|
|
2020
Q3 | $627K | Buy |
49,781
+2,076
| +4% | +$26K | ﹤0.01% | 4184 |
|
|
2020
Q2 | $578K | Buy |
47,705
+9,707
| +26% | +$103K | ﹤0.01% | 4223 |
|
|
2020
Q1 | $292K | Sell |
37,998
-5,353
| -12% | -$72.2K | ﹤0.01% | 4431 |
|
|
2019
Q4 | $773K | Sell |
43,351
-934
| -2% | -$12.2K | ﹤0.01% | 4035 |
|
|
2019
Q3 | $513K | Buy |
44,285
+8,575
| +24% | +$139K | ﹤0.01% | 4357 |
|
|
2019
Q2 | $791K | Buy |
35,710
+1,103
| +3% | +$25.9K | ﹤0.01% | 4063 |
|
|
2019
Q1 | $990K | Buy |
34,607
+88
| +0.3% | +$1.91K | ﹤0.01% | 3885 |
|
|
2018
Q4 | $682K | Buy |
34,519
+7,451
| +28% | +$150K | ﹤0.01% | 4126 |
|
|
2018
Q3 | $598K | Buy |
+27,068
| New | +$366K | ﹤0.01% | 4316 |
|
|
2016
Q2 | – | Sell |
-165
| Closed | -$1K | – | 6209 |
|
|
2016
Q1 | $1K | Buy |
165
+160
| +3,200% | +$2.87K | ﹤0.01% | 6099 |
|
|
2015
Q4 | $0 | Hold |
5
| – | – | ﹤0.01% | 6323 |
|
|
2015
Q3 | $0 | Sell |
5
-39
| -89% | -$3.32K | ﹤0.01% | 6317 |
|
|
2015
Q2 | $4K | Buy |
+44
| New | +$4.37K | ﹤0.01% | 6054 |
|
Other funds holding KALV
VA
FLSM
SCM
TCM
SCM
Wells Fargo's KALV Position: Q1 2026 in Review
Wells Fargo reduced its KalVista Pharmaceuticals (KALV) stake by 57% in Q1 2026, selling an estimated $517K and leaving 23,927 shares worth $482K. The position accounts for ﹤0.01% of the portfolio, ranked #4193.
Wells Fargo first reported a position in KALV in Q2 2015 and has held it in 35 quarters since. The position peaked at $2.07M in Q2 2021. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.
- Wells Fargo held 23,927 shares of KalVista Pharmaceuticals worth $482K as of Q1 2026.
- Wells Fargo sold 32,087 KalVista Pharmaceuticals shares in Q1 2026, an estimated $517K.
- KalVista Pharmaceuticals made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #4193 holding.
- Wells Fargo first reported a position in KalVista Pharmaceuticals in Q2 2015 and has held it in 35 quarters since.
- Wells Fargo's KalVista Pharmaceuticals position peaked at $2.07M in Q2 2021.
- 183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.
Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.